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Abstract 
Retinoic Acid Receptor Responder (RARRES1) initially identified as a novel retinoic acid 
receptor regulated gene in the skin is a putative tumor suppressor of unknown function. 
RARRES1 was knocked down in immortalized human prostatic epithelial cell line PWR-1E 
cells and differential protein expression was identified using differential in-gel electrophoresis 
(DIGE) followed by matrix-assisted laser desorption ionization (MALDI) mass spectrometry 
and western Blot analysis excluding highly abundant proteins routinely identified in almost all 
proteomics projects. Knock-down of RARRES1: 1- down-regulates PP2A, an enzyme involved 
in the negative regulation of the growth hormone-stimulated signal transduction pathways; 2- 
down-regulates Valosin-containing protein causing impaired autophagy; 3- up-regulates the 
tumor suppressor disks large 2; 4- up-regulates Ankrd26 that belongs to the POTE family of 
genes that are highly expressed in cancer patients with poor outcome; and 5- down-regulates 
EB1, a protein that is involved in spindle dynamics and chromosome alignment during mitosis.  
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1. Introduction 
Retinoic acids (RA) are ligands which signal 
through a family of six nuclear ligand-activated re-
ceptors, termed retinoic acid receptors (RARα, β, and 
γ) and retinoid X receptors (RXRα, β, and γ) (1). These 
receptors form RXR/RXR homodimers or RAR/RXR 
heterodimers and bind to retinoic acid response ele-
ments (RARE) in DNA (1, 2). In the absence of RA, the 
RAR/RXR heterodimers bind to RARE and mediate a 
transcriptional repression of target genes (3). In con-
trast, when stimulated with physiological levels of 
RA, the ligand binding induces a conformational 
change in the dimer and causes a release of the core-
pressor complex and a subsequent recruitment of 
transcriptional coactivators, thereby stimulating 
transcription of target genes such as HOX family 
members. Interestingly, RXRs have proven quite 
promiscuous, having been shown to facilitate binding 
of thyroid hormone receptor (TR) and the vitamin D 
receptor (VDR) to their respective response elements 
in DNA, indicating a broad role in the transcriptional 
events of many cell types (2). RA has a profound im-
pact on vertebrate embryogenesis. RA has been de-
scribed as a morphogen which is fundamental in 
proper embryonic patterning, especially in the 
rhombomeric region of the developing brain (4). Em-
bryonic RA signaling is also crucial in the augmenta-
tion of cell survival, proliferation and differentiation 
(5). These observations have made RA the focus of 
research into its use as a front-line therapy in the 




RARRES1 was initially identified as a novel re-
tinoic acid receptor (RARβ/γ) regulated gene in the 
skin (6). Several reports have implicated RARRES1 as 
a putative tumor suppressor genes based largely on 
the hypermethylation of its promoter in many tumor 
types and ageing normal tissues (7-14). Studies in-
volving the re-expression of RARRES1 have also 
pointed to its tumor suppressive function, as it de-
creased the growth of aggressive PC-3M prostate 
cancer cells and Ishikawa endometrial cancer cells (10, 
16). RARRES1 also greatly reduced the in vitro inva-
siveness and in vitro tumor growth of the PC-3M 
prostate cancer cells in nude mice (16). Recently, 
RARRES1 expression has been linked to the prolifera-
tion and differentiation of adult adipose-derived me-
senchymal stem cells (17). RARRES1 expression was 
substantially reduced in the majority of cancer cell 
lines and was undetectable in 7 of them; furthermore, 
a significant reduction of RARRES1 has been ob-
served in advanced and poorly differentiated tumors 
(18). 
Here we report the mimicking of RARRES1 
hypermethylation by knocking it down in PWR-1E 
cells. Proteins were then extracted from the 
knocked-down and control samples, were subjected 
to 2-D DIGE followed by MALDI-TOF/TOF analysis 
to identify the differentially expressed proteins sec-
ondary to the knock down. Since proteins don’t act 
individually but rather in a network, we identified the 
proteins that are affected by the down-regulation of 
RARRES1 to be: Disk-large-2, PP2A, VCP, EB1, and 
Ankrd26. 
2. Materials and Methods 
2.1 Cell Culture and Nucleofection 
PWR-1E cells passage 18 (ATCC CRL-11611) 
were cultured in Keratinocyte Serum Free Medium 
(K-SFM) supplemented with 0.05mg/mL of bovine 
pituitary extract (BPE) and 5ng/mL epidermal 
growth factor (EGF). Cells were nucleofected using 
the Cell line Nucleofector Kit V (Amaxa inc., Gai-
thersburg, MD), program T-20, and 200 picomole of 
RARRES1 or scrambled siRNA per million cells ac-
cording to the manufacturer’s instructions. A total of 
four biological replicates were performed for each 
sample and control. 
2.2 Protein Extraction and Quantitation 
Cells were harvested 48 hrs after nucleofection. 
Cells that were cultured in 100mm dishes were briefly 
rinsed with PBS, incubated with 3mL of a 0.05% tryp-
sin – 0.53 mM EDTA solution, diluted 1:1 with PBS 
and incubated for 5 minutes at 37ºC. Cells were then 
transferred to a centrifuge tube, washed 3 times with 
PBS, each time centrifuging and discarding the su-
pernatant. Cells were then collected and lysed with a 
buffer composed of 30 mM Tris-HCl, 7 M Urea, and 
4% CHAPS. The lysates were then vortexed for 1 hour 
at 4ºC followed by a centrifugation at 15,000xg for 15 
minutes. Unsoluble pellets were discarded. Proteins 
were then quantified as described previously (19) 
using a Protein Assay (cat # 500-0006) according to the 
manufacturer’s description (Bio-Rad, Hercules, CA). 
Protein concentrations were then diluted with the 
same lysis buffer to a final concentration of 5mg/mL. 
2.3 Protein-Dye Labeling for 2D-DIGE Analysis 
CyDye DIGE Fluor minimal dyes were recons-
tituted in water free DMF to a final concentration of 
200pmole/µL. 25µg of each of the 4 biological repli-
cates of RARRES1 Knockdown or control samples 
were labeled with 200 pmoles of either Cy3 or Cy5. 
Cy3 and Cy5 were equally swapped among RARRES1 
Knockdown and control samples. Upon addition of 
the dyes, samples were vigorously vortexed and kept 
on ice in the dark for 30 min. The labeling reaction 
was quenched by adding 10 µL of a 10 mM lysine 
solution followed by vortexing. An internal standard 
sample composed of equal amounts of both condi-
tions was labeled with Cy2 dye using the same pro-
cedure. Labeled proteins were pooled into 4 different 
fractions according to Table 1. Each fraction was di-
luted with rehydration buffer (50 mM Tris-HCl pH 
8.8, 6 M Urea, 4% CHAPS (w/v), 1% DTT (w/v), 1% 
Bio-lyte 3/10 Ampholyte) to a final volume of 450 µL. 
2.4 2D DIGE 
Isoelectric focusing (IEF) was performed by re-
hydrating the 24 cm IPG strips pH 3-10 non-linear for 
8 hours at 50 V in 450 µL of sample in rehydration 
buffer. The rehydration step was followed by focusing 
the proteins using the following series of step and 
hold voltages: 250 V for 30 min, 500 V for 30 min, 1000 
V for 1 hr, 3000 V for 3 hrs. An 8000 V was then 
maintained for a total of 65,000 Vh. IPG strips were 
then incubated in a reducing buffer composed of 50 
mM Tris-HCl pH 8.8, 6 M Urea, 2% SDS (w/v), and 
1% DTT (w/v) for 15 min. A second incubation was 
performed in an alkylating buffer composed of 50 mM 
Tris-HCl pH 8.8, 6 M Urea, 2% SDS (w/v), and 4% 
iodoacetamide (w/v) and 0.01% bromophenol blue 
for 15 min. Strips were then placed onto a 5-20% gra-
dient gel that has 2 built-in spot picking references 
(Nextgensciences, Ann Arbor, MI). Gels were then 
loaded into an Ettan DALTsix buffer tank (GE 
Healthcare) filled with SDS electrophoresis buffer. 
Proteins were electrophoresed overnight at 8 W until 




buffer temperature was maintained at 10ºC through-
out the separation. The analytical gels (Gels 1 to 4 
Table 1) were scanned right after the end of the sepa-
ration as described below while the “pick gel” (Gel 5, 
Table 1) was fixed for 6 hrs with a solution containing 
30% methanol and 7.5% acetic acid followed by over-
night incubation with Sypro Ruby stain (Bio-Rad, 
Hercules, CA). The gel was then incubated in des-
taining solution (10% methanol, 7% acetic acid) for 3 
hrs before proceeding with the scanning step.  
 
Table 1. Sample mixture loaded on each gel: Each sample was composed of equal amounts of RARRES1 knock-down 
PWR-1E and control lysates. Cy3 and Cy5 dyes were equally swapped among RARES1 knock-down and control samples. 
The internal standard was labeled with Cy2 and consisted of 12.5 µg of each knock-down and control. The sample loaded on 
the pick-gel was composed of 300 µg of each sample and control. 
  RARRES1 KNOCKDOWN SAMPLE  CONTROL  INTERNAL STANDARD 
      
Fraction 1/GEL 1  25 µg labeled with Cy3  25 µg labeled with Cy5  25 µg labeled with Cy2 
Fraction 2/GEL 2  25 µg labeled with Cy3  25 µg labeled with Cy5  25 µg labeled with Cy2 
Fraction 3/GEL 3  25 µg labeled with Cy5  25 µg labeled with Cy3  25 µg labeled with Cy2 
Fraction 4/GEL 4  25 µg labeled with Cy5  25 µg labeled with Cy3  25 µg labeled with Cy2 
PICK GEL  300 µg non-labeled  300 µg non-labeled   
 
 
Table 2. Identified proteins: Table of proteins that were differentially expressed across the 4 biological replicates with a 
t value < 0.05 and that were identified with a significant MASCOT interval of confidence (p < 0.05). Among the identified 
proteins, 31 highly abundant, structural proteins, HSPs as well as proteins that are repeatedly identified as being differen-
tially-expressed were omitted from this list. 
T-test  Av. Ratio  Protein Name 
     
0.0054  -1.36  P55072|TERA_HUMAN Transitional endoplasmic reticulum ATPase - Homo sapiens (Human) 
0.044  -1.36  P13798|ACPH_HUMAN Acylamino-acid-releasing enzyme - Homo sapiens (Human) 
0.0072  1.21  Q15700|DLG2_HUMAN Disks large homolog 2 - Homo sapiens (Human) 
1.20E-05 -1.73  P30153|2AAA_HUMAN Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform – 
(Human) 
0.031  -1.14  O00303|EIF3F_HUMAN Eukaryotic translation initiation factor 3 subunit F - Homo sapiens (Human) 
0.048  1.19  A5A3E0|A26CB_HUMAN ANKRD26-like family C member 1B - Homo sapiens (Human) 
0.047 -1.19  Q15293|RCN1_HUMAN  Reticulocalbin-1 precursor - Homo sapiens (Human) 
0.0032  -1.49  Q9UNZ2|NSF1C_HUMAN NSFL1 cofactor p47 - Homo sapiens (Human) 
0.042 -1.23  P08700|IL3_HUMAN  Interleukin-3 precursor - Homo sapiens (Human) 
0.0039  1.17  Q99829|CPNE1_HUMAN Copine-1 - Homo sapiens (Human) 
0.0041 1.18  P06748|NPM_HUMAN  Nucleophosmin  - Homo sapiens (Human) 
0.034  -1.18  Q15691|MARE1_HUMAN Microtubule-associated protein RP/EB family member 1 - Homo sapiens (Human) 
0.042  -1.24  P49411|EFTU_HUMAN Elongation factor Tu, mitochondrial precursor - Homo sapiens (Human) 
0.049  1.1  P63104|1433Z_HUMAN 14-3-3 protein zeta/delta - Homo sapiens (Human) 
0.02  -1.27  P62714|PP2AB_HUMAN Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform - Homo sapiens 
(Human) 
0.039 -1.15  P21796|VDAC1_HUMAN  Voltage-dependent  anion-selective channel protein 1 - Homo sapiens (Human) 
0.048  1.15  Q9HCY8|S10AE_HUMAN Protein S100-A14 - Homo sapiens (Human) 
0.027  1.25  P31949|S10AB_HUMAN Protein S100-A11 - Homo sapiens (Human) 
0.035  1.44  P31949|S10AB_HUMAN Protein S100-A11 - Homo sapiens (Human) 
 
 




2.5 Gel Scanning and Image Analysis 
Gels were scanned using an Ettan DIGE Imager 
(GE Healthcare) at 100µm size. Appropriate laser ex-
posure times were used so that no protein spot is sa-
turated and all spot intensities fall within the linear 
range. The analytical gel images were cropped using 
ImageQuant TL (GE Healthcare) to get rid of the 
smears on gel edges. Image analysis was then per-
formed using DeCyderTM2D 6.5 software. Cropped 
images of the analytical gels were loaded using the 
Image Loader tool of the software and spot detection 
and matching was performed using the Batch Pro-
cessor tool while applying the following spot filtering 
parameters: Slope > 1.1 ; Area < 100 ; Peak Height < 
100 ; and Volume < 65,000. Automatic spot matching 
was followed by a manual confirmation and re-
matching of unmatched or mistakenly matched spots. 
Inter-gel analysis and calculation of average protein 
abundance ratios were performed using the Biological 
Variation Analysis (BVA) tool. A Student’s t-test was 
applied to generate a list of differentially-expressed 
spots between control and RARRES1 Knockdown 
PWR-1E protein extracts. 
2.6 Spot Excision and Digestion 
The “pick gel” image was matched with the 
analytical gel images using the BVA tool of the De-
CyderTM2D v.6.5 software. A spot pick list coordinates 
was generated for proteins that were differential-
ly-expressed within the 4 biological replicates with a p 
value of 0.05 or less. The coordinates of the 2 internal 
references were included in the pick list that was ex-
ported into the Spot Picker v1.2 which is the driver for 
the Ettan Spot Picker instrument (GE Healthcare). The 
“Pick Gel” was then placed in the gel holder plate. 
The spot picker was calibrated using the internal ref-
erences and spots were than excised in ultrapure wa-
ter and transferred into a 96-well ZiplateC18 (Cat # 
ZPC180010, Millipore, Bedford, MA). Protein diges-
tion and peptide recovery procedures were modified 
from the manufacturer’s instructions as follows: Gel 
pieces were dehydrated by adding 200 µL of acetoni-
trile to each well followed by 10 minute incubation. 
Full vacuum was then applied to elute the acetonitrile 
through the C18 resin forming the bottom of the Zip-
late. Gel pieces were then rehydrated by adding 15 µL 
of a 25 mM ammonium bicarbonate containing 5 
ng/µL of modified trypsin. After overnight incuba-
tion at 37ºC, 8 µL of acetonitrile was added to the re-
sin. After 12 minutes of incubation, 100 µL of 0.2% 
TFA ultrapure water solution was added to each well 
and incubated for 30 minutes. The 96-well plate was 
then placed on a vacuum plate holder to empty wells. 
A final washing step was performed with a 100 µL of 
0.2% TFA ultrapure water solution followed by va-
cuum to empty wells. The Zipplate was then placed 
upon a low retention 96-well “V” bottom plate (cat# 
2897, Corning Inc., Corning, NY) and tryptic digests 
were eluted by adding 8 µL of acetonitrile followed by 
centrifugation at 3000xg. The bottom plate was left to 
air dry. Peptides were reconstituted with 2 µL of a 2.5 
mg/mL α-cyano-4-hydroxycinnamic acid matrix so-
lution. The matrix solvent was composed of 49.95% 
water, 49.95% acetonitrile, and 0.1% TFA (v/v/v). The 
peptide-matrix mixture was then deposited onto a 
MALDI target plate and allowed to air dry. 
2.7 MALDI TOF and TOF/TOF Analysis 
MS and MS/MS analysis were performed using 
a 4800 MALDI TOF/TOF mass spectrometer (Applied 
Biosystems, Foster city, CA). The instrument was ca-
librated using Applied Biosystems calibration stan-
dards. MALDI-TOF spectra were acquired by accu-
mulating 1000 laser shots in reflector mode for posi-
tive ion detection between 800 and 4000 m/z. The 
most intense 15 peaks with S/N of 10 or higher were 
selected for MS/MS analysis excluding the commonly 
observed peaks for trypsin. Argon was used as the 
collision gas.  
2.8 Protein Identification 
Protein were identified as described previously 
(20). Briefly, MS and MS/MS Mass lists were picked 
by the GPS Explorer v3.5 software and submitted to 
the MASCOT v.2.0.00 search engine. The settings that 
were used were the following: database: Swiss-Prot; 
Taxonomy:  homo sapiens; Enzyme: trypsin; Variable 
modifications: carbamidomethyl (C) and Oxidation 
(M); MS/MS fragment tolerance: 0.3Da; Precursor 
mass tolerance: 75 ppm; Maximum missed cleavage 
allowed: 1. Only proteins with MASCOT confidence 
interval higher than 95% (p < 0.05) were considered. 
Experimental molecular mass a n d  p I  w e r e  u s e d  t o  
confirm protein identities. 
2.9 Western Blotting 
  Western Blotting was performed as described 
previously (21) using the following antibodies: Rabbit 
monoclonal to PP2A (cat. ab32141, Abcam, Cam-
bridge, MA); Rabbit polyclonal to PSD93 (cat. ab2930, 
Abcam, Cambridge, MA); Goat polyclonal to 
RARRES1 (R&D systems, Mineapolis, MN); Mouse 
monoclonal to VCP (cat. ab11433, Abcam, Cambridge, 
MA). 
3. Results and Discussion 
RARRES1 knockdown in PWR-1E cells was va-
lidated using western blot that shows the significant 




RARRES1 siRNA nucleofection when compared to 
RARRES1 expression in the scrambled siRNA nuc-
leofected cells. Relative protein expression change 
that resulted from RARRES1 knockdown in PWR-1E 
cells was assessed by DIGE. A total of 8121 spots were 
detected on the 2-dimensional gels (Figure 1) of which 
97 spots were consistently differentially-expressed 
with a p < 0.05 across the 4 biological replicates. An 
advantage of DIGE over regular 2-D gel techniques is 
the elimination of gel to gel variations since both 
sample and control are run on the same gel and nor-
malized based on the internal standard pool which is 
also run on the same gel. Only spots with level 
changes of 10% or more were considered. These spots 
were matched and excised from the pick gel (Figure 2) 
and processed for MALDI-MS/MS analysis (21) that 
allowed for the identification of 50 proteins. Differen-
tially-expressed proteins that were identified included 
highly abundant proteins (e.g. tubulin), heat shock 
proteins (e.g. HSP 90) in addition to other proteins that 
are repeatedly identified as being differential-
ly-expressed (e.g. peroxiredoxins, enolases, piruvate 
kinases) (22). These proteins were not considered in 
the study. Emphasis was given to proteins that are 
involved in the regulation of cell cycle. Of particular 
interest were Disks large homolog 2 (Dlg-2), Se-
rine/threonine-protein phosphatase (PP2A), and Va-





Figure 1. DIGE data: Representation set of one of the 4 biological replicates. 25 µg of control PWR-1E cells lysates 
labeled with 200 pmoles of Cy3 (green); 25 µg of RARRES1 knock-down PWR-1E cells labeled with 200 pmoles of Cy5 (red) 
and a normalization pool composed of a 50:50 mixture of sample and control labeled with Cy2 (blue). The first dimension 
separation was performed on a 24 cm non-linear IPG strips and the second dimension separation was accomplished on a 
5-20% gradient polyacrylamide gel with 2 built-in spot picking references. Gels were scanned at a 100 µm resolution using 
excitation and emission wavelength that corresponds to each dye. Combined Cy2, Cy3, and Cy5 signals are represented in 





Figure 2. Sypro Ruby Pick gel: loaded with 300µg of PWR-1E RARRES1 knock-down protein extracts and 300µg of 
control sample. The green dots represent the proteins that were detected by the Decyder software. Annotated proteins are 
those that were picked for mass spectrometry analysis. These spots were identified as differentially-expressed across the 4 
biological replicates in the analytical gels. The coordinates of these spots were recorded, matched, and excised from the Pick 
gel for identification.  
 
 
Figure 3. Differentially expressed proteins: a) 2- Cropped DIGE; b) three-dimensional view, and c) logarithmic 
representation of the 4 four biological replicates of Dlg-2 upregulation, PP2A and VCP down-regulation as a result of 




Retinoic Acid Receptor Responder 1 (RARRES1) 
is a putative carboxypeptidase inhibitor and tumor 
suppressor which gene is frequently silenced in can-
cer and aging normal cells. RARRES1 knock-down in 
PWR-1E cells resulted in the upregulation of disks 
large 2 (Dlg2), a neoplastic tumor suppressor that acts 
as a scaffold at cell-cell junctions (23-25). Dlg2 consists 
exclusively of protein-protein interaction domains 
and PDZ domains implicated in cell polarity control 
and is localized basal to the adherens junctions (26, 
27). Dlg2 homologue was found to be upregulated in 
oncocytoma, a benign tumor of the kidney and is 
therefore considered an oncogene (28). RARRES1 
knock-down resulted also in the down-regulation of 
serine/threonine-protein phosphatase 2A (PP2A) in 
addition to its catalytic subunit. PP2A has broad sub-
strate specificity. It targets proteins of oncogenic sig-
naling cascades including Raf, Mek, and Akt (29). 
PP2A is a negative regulator of the growth hormone 
stimulated signal transduction pathways. Mutation of 
this enzyme has been identified in several types of 
cancer including lung (30, 31) and breast (32-36). Its 
down-regulation secondary to RARRES1 knock-down 
results in a decreased targeting of Raf, Mek, and Akt. 
Furthermore Valosin-containing Protein (VCP) was 
also down-regulated as a result of RARRES1 
knock-down. Mutation of VCP causes inappropriate 
activation of NFκB signaling cascade (37) as well as 
impaired autophagy (38). End-bindin protein-1 (EB1) 
was found to be down-regulated as a result of 
RARRES1 knock-down. EB1 is mainly involved in the 
regulation of spindle dynamics and chromosome 
alignment during mitosis (39) and promotes micro-
tubule growth by suppressing catastrophes (40). It 
was recently shown to promote colony formation and 
enhancing tumor growth in nude cells while its 
knock-down resulted in the inhibition of cancer cell 
proliferation suggesting an oncogenic role (41). As for 
Ankrd26, it belongs to the POTE family of genes con-
taining ankyrin repeat and coiled coil domains (42). 
Ankrd1 has recently been found to be expressed in the 
majority of ovarian adenocarcimoas and found at 
high levels in patients with worse outcome (43). 
Western blotting was performed to validate the 
upregulation of Dlg-2 and down-regulation of PP2A 
and VCP (Figure 4) as a result of RARRES1 
knock-down. 
While the down-regulation of VCP and PP2A 
and the up-regulation of Ankrd26 are consistent with 
the knock-down of tumor suppressor RARRES1, on-
cogenic EB1 down-regulation and tumor suppressor 
dlg2 up-regulation following RARRES1 knock-down 
are thought to have occurred to compensate for the 
loss of RARRES1 expression.  
 
 
Figure 4. Western Blot Validation: of a) RARRES1 
knock-down, b) Dlg2 homologue, c) PP2A, d) VCP and e) 
GAPDH loading control. Lane 1 scrambled siRNA nuc-
leofected PWR-1E lysates; lane 2 RARRES1 siRNA nuc-
leofected PWR-1E lysates. 
 
Conclusion 
Our analysis shows that knock-down of 
RARRES1 exhibits a consistent change in the expres-
sion level of several proteins notably up-regulation of 
Dlg2, a neoplastic tumor suppressor, down-regulation 
of VCP that results in the activation of NFκB signaling 
cascade, down-regulation of PP2A that results in a 
decreased targeting of oncogenes Raf, Mek, and Akt, 
up-regulation of Ankrd26, a member of the POTE 
family of genes, and down-regulation of EB1. This 
data highlights the role of RARRES1 and as a conse-
quence that of retinoic acid as a tumor suppressor. 
More studies are required to test which one of these 
molecules interacts directly with RARRES1 to eluci-
date its mechanism of tumor suppressing. 
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